Post-operative application of CsA

PreclinicalSmall molecule

Post-operative application of CsA is one of 8 small molecule programs targeting Pterygium. It is currently in Preclinical.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

PterygiumActive, not recruiting

PterygiumPreclinical

Active, not recruiting

Competition

Competitive Landscape

8 competitors in Pterygium

#DrugCompanyPhaseTrials

Trexall

Jazz Pharmaceuticals

Approved

1 2

Pred Forte

Novartis

Approved

1 3

Mitosol

UUroGen Pharma Ltd.

Approved

—4

CBT-001

CCloudbreak Therapeutics, LLC

Phase 3

2 5

Oxylone

AbbVie

Preclinical

1 6

Tripterygium

NNanjing University School of Medicine

Preclinical

1 7

Enteral Nutrition

JJagiellonian University

Preclinical

1 8

Post-operative application of CsA

BBenha University

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Pterygium1 trial

CsA vs MMC for Preventing Pterygium Recurrence

Completed·—·N/A·NCT06944132·40 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for Post-operative application of CsA. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Post-operative application of CsA compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Post-operative application of CsA. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Benha University company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Preclinical[1]
Company: BBenha University

Post-operative application of CsA

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Pterygium1 trial

References

Drug Info

Quick Facts

Related News